European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.
Sanofi decided to stop trying to get approval for one use of its medicine Dupixent because the tests didn't work out perfectly. When a company pulls back a medicine plan, it means they hit a bump—watch if this slows their growth or if they focus on other winning medicines instead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.